Skip to Main Content

As the Biden administration assumes leadership in Washington and former President Donald Trump’s most-favored nation ruling has been halted by a federal judge, drug price controls don’t feel imminent.

Though this should provide some relief to the R&D-based biopharmaceutical industry, the relief may be short-lived.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • I hope the author had compared each healthcare system. In USA with the mutually subsidized healthcare system no one even the author knows any pricing at any point in the supply chain. Then we have BIG GORILLA (PBM and insurance companies) who don’t want to change the current system as their golden goose will disappear. Till nationalized nothing will change. Politicians will make sure that nothing is altered.

    Has the author reviewed the workings of the current system? He should. Pundits have written, are writing and will be writing in 2050. No change will happen.

Comments are closed.